U.S. markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.90 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.44 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.53
    -0.18 (-0.39%)
     
  • Gold

    1,788.10
    -23.10 (-1.28%)
     
  • Silver

    22.64
    -0.81 (-3.44%)
     
  • EUR/USD

    1.1970
    +0.0057 (+0.48%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • GBP/USD

    1.3314
    -0.0042 (-0.32%)
     
  • USD/JPY

    104.0850
    -0.1650 (-0.16%)
     
  • BTC-USD

    17,748.03
    +562.69 (+3.27%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

Omnicell: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Omnicell (NASDAQ:OMCL) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 21.05% year over year to $0.60, which beat the estimate of $0.49.

Revenue of $213,699,000 decreased by 6.60% year over year, which beat the estimate of $208,460,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $1,015,000,000 and $1,045,000,000.

Conference Call Details

Date: Oct 27, 2020

View more earnings on OMCL

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/gyjj6bpt

Recent Stock Performance

52-week high: $94.85

Company's 52-week low was at $54.24

Price action over last quarter: Up 17.81%

Company Description

Omnicell provides automation and business analytics software for healthcare providers. The firm operates in two segments: automation and analytics and medication adherence. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. This segment contributes the majority of revenue. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.